CDK4/6 inhibitorFDA-approvedSecond-line
Abemaciclib
How it works
Blocks the activity of cyclin-dependent kinases 4 and 6, which are involved in cell growth and division, thereby inhibiting tumor growth.
Cancer types
Breast Cancer— Hormone receptor-positive
Efficacy
In clinical trials, abemaciclib in combination with an aromatase inhibitor improved progression-free survival in patients with hormone receptor-positive, HER2-negative metastatic breast cancer compared to those who received an aromatase inhibitor alone.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Abemaciclib and Hydroxychloroquine for Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Abemaciclib and Endocrine Therapy for Older Patients with Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Abemaciclib and Letrozole in Rare Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Breast Cancer Treatment Trial Examines Abemaciclib and Endocrine Therapy | Breast Cancer | phase-3 | — | Source → |
| Evaluating Lasofoxifene and Abemaciclib vs. Fulvestrant and Abemaciclib for Advanced Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Testing Combination of Anti-cancer Drugs for Rare Cancers | Breast Cancer | phase-1 | — | Source → |
| Testing Abemaciclib with Chemotherapy for Advanced Colorectal Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Testing New Treatments for Advanced Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Breast Cancer Treatment Study | Breast Cancer | preclinical | — | Source → |
| Testing Chemotherapy vs Hormone Therapy with Abemaciclib in Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Abemaciclib Fails to Meet Primary Endpoint in Brain Metastases Study | Lung Cancer | phase-2 | A volumetric decrease in target intracranial lesions was 22.7% for NSCLC and 18.8% for melanoma cohorts. | Source → |
| Combining Ferulic Acid with Breast Cancer Drugs May Improve Treatment | Breast Cancer | lab-study | — | Source → |
| Abemaciclib May Cause Skin Reactions in Breast Cancer Patients | Breast Cancer | observational | — | Source → |
| New Combination Therapy Tested for Advanced Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Combination Therapy Shows Promise in Rare Male Breast Cancer | Breast Cancer | observational | — | Source → |
| Managing Diarrhea in Breast Cancer Patients with Abemaciclib | Breast Cancer | observational | Severe (G3) diarrhea was significantly less frequent in the Postbio group (0%) compared to the Standard one (7.9%; P = .029). | Source → |
| Abemaciclib Shows Promise in Treating Advanced Prostate Cancer | Prostate Cancer | phase-2 | The objective response rate without concurrent bone progression was 6.8%. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.